PhaseBio Pharmaceuticals, Inc.
Methods and compositions for treating cystic fibrosis

Abstract:

The present disclosure provides a method of treating diseases or disorders associated with CFTR protein dysfunction, including Cystic Fibrosis, by administering stable, long-lasting vasoactive intestinal peptide therapeutic agents. These agents include one or more elastin-like peptides and can be administered at a low-dose.